Bora-Pharmaceuticals-Header Bora-Pharmaceuticals-Header


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type


            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): MIT-001

            Therapeutic Area: Gastroenterology Product Name: MIT-001

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 06, 2021


            MIT-001 is an anti-inflammatory and anti-necrotic agent, specifically scavenging ROS in the mitochondria. MitoImmune plans to initiates a Phase 2 trial of oral mucositis (OM) prevention and is expanding OM treatment into hematopoietic stem cell transplantation.